CV Therapeutics begins shipping angina drug Ranexa to wholesalers

By E. Janene Geiss

Philadelphia, March 10 - CV Therapeutics, Inc. said Friday that the company has begun filling orders and shipping Ranexa (ranolazine extended-release tablets) to pharmaceutical wholesalers.

The company said it anticipates that Ranexa will be available in pharmacies by late March when the company's cardiovascular sales force expects to begin calling on cardiology specialists, company officials said in a news release.

On Jan. 27, the Food and Drug Administration approved Ranexa for marketing in the United States.

The approval marks the first new pharmaceutical approach to treat angina in more than 20 years in the United States, officials said.

Ranexa has anti-anginal and anti-ischemic effects that do not depend upon reductions in heart rate or blood pressure, officials said. According to the approved product labeling, Ranexa is indicated for the treatment of chronic angina.

CV Therapeutics is a Palo Alto, Calif., biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.